RECRUITING

PET Imaging CCR2 in Lung Inflammation

Talk to us

Conditions

Lung Inflammation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.

Official Title

PET Imaging CCR2 in Lung Inflammation

Quick Facts

Study Start:2018-02-27
Study Completion:2026-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03492762

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Men or women 21 years of age or older who have never smoked or current smokers who smoked at least 10 cigarettes per day (1/2 pack) and have smoked at least 100 cigarettes (5 packs) over the past month.
  2. * Screening FEV1 and FVC \> 80% of predicted
  3. * Capable of lying still and supine within the PET/CT and PET/MR scanner for \~1 hour and follow instructions for breathing protocol during the CT portion
  4. * No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year
  5. * No known history of cardiac, pulmonary, hepatic or renal disease or diabetes
  6. * No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol specified imaging sessions
  7. * Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol
  8. * BMI ≤ 35
  1. * Currently enrolled in another study using an investigational drug
  2. * Pregnancy (confirmed by urine pregnancy test)
  3. * Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes
  4. * Currently taking any prescription medications
  5. * Presence of an implanted device that is incompatible with CT or MRI scanning
  6. * Creatinine \> 1.30 mg/dL, AST \> 50 Units/L, ALT \> 55 Units/L, or total bilirubin \> 1.2 mg/dL

Contacts and Locations

Study Contact

Steven Brody, MD
CONTACT
314-362-8969
brodys@wustl.edu

Principal Investigator

Steven Brody, MD
PRINCIPAL_INVESTIGATOR
Washington University School of Medicine

Study Locations (Sites)

Washington University School of Medicine
Saint Louis, Missouri, 63110
United States

Collaborators and Investigators

Sponsor: Washington University School of Medicine

  • Steven Brody, MD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-02-27
Study Completion Date2026-08-31

Study Record Updates

Study Start Date2018-02-27
Study Completion Date2026-08-31

Terms related to this study

Additional Relevant MeSH Terms

  • Lung Inflammation